Discovery

  1. Advancing Hematology and Cell Therapy Innovation with AstraZeneca's Aliya Omer 11/4/2025

    On episode 115 of Cell & Gene: The Podcast, Host Erin Harris talks to Aliya Omer, Vice President and Global Head of Hematology and Cell Therapy at AstraZeneca, who shares valuable insights from her rich experience leading cell therapy development across multiple top companies.

  2. The Intersection Of RNA, AI, And Synthetic Biology With Shape Therapeutics' Dr. Francois Vigneault 7/18/2023

    Dr. Francois Vigneault, Co-Founder, President, and CEO at Shape Therapeutics joins Cell & Gene: The Podcast's Erin Harris to discuss how RNA technologies are shaping the future of gene therapy. They also discuss AI's role in gene therapy as well as how the CGT sector is benefiting from RNA, AI, and synthetic biology.

  3. Gene Therapy for Inherited Retinal Diseases with Opus Genetics' Dr. George Magrath 7/1/2025

    In this episode of Cell & Gene: The Podcast, George Magrath, CEO of Opus Genetics, shares with Host, Erin Harris, how the company is advancing gene therapies for inherited retinal diseases (IRDs), with a focus on LCA5, a rare and severe form of childhood blindness.

  4. Inside CRISPR-GPT With Yuanhao Qu 8/26/2025

    In this episode of Cell & Gene Podcast episode, Host Erin Harris talks to Stanford School of Medicine Ph.D. student, Yuanhao Qu, about his work developing CRISPR-GPT, an AI-driven multi-agent system designed to automate genetic experimental design and data analysis, making CRISPR experiments more efficient and accessible, even for non-experts.

  5. Can Gene Therapy Be The Solution For CHF With AskBio's Dr. Lothar Roessig 12/18/2024

    Lothar Roessig, M.D., SVP, Integrated Product Team Lead, Congestive Heart Failure at Asklepios BioPharmaceutical, Inc. (AskBio) discusses the biggest challenges in developing gene therapies for cardiovascular diseases.

  6. Globalization's Impact on Patient Access with ARM's COO, Rita Johnson-Greene 11/20/2024

    Rita Johnson-Greene, COO at Alliance for Regenerative Medicine (ARM) joined Cell & Gene: The Podcast Host, Erin Harris, on-site during the 2024 Meeting on the Mesa to record their discussion. Johnson-Greene shared information about the Joint Clinical Assessment (JCA) in Europe and its potential impact on cell and gene therapies, how globalization impacts patient access, an update on ARM's Grow Internship Program, as well as a few key takeaways from the event that sector professionals can anticipate impacting the CGTs in the next 12 months and beyond.

  7. Turning the Tumor Microenvironment Against Cancer with MGB's Alexander Cryer, Ph.D. 12/12/2025

    In Episode 118, Host Erin Harris talks to Alexander Cryer, Ph.D., Instructor in Medicine at Mass General Brigham, about a proof-of-concept strategy that reprograms tumor cells with mRNA lipid nanoparticles to overactivate the cGAS-STING pathway, forcing cancer cells to produce and export large amounts of the innate immune agonist cGAMP to stimulate surrounding immune cells and drive anti-tumor immunity.

  8. TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D. 7/4/2024

    KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. 

  9. The Future of NK Cell Therapy for Autoimmune Disease with Artiva Biotherapeutics' Christopher Horan 1/15/2025

    Christopher Horan, Chief Technical Operations Officer, Artiva Biotherapeutics joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the advantages natural killer (NK) cells have offer over T cells in terms of safety and efficacy for autoimmune disease. They take a deep dive into the key factors that make NK cells promising for ‘off-the-shelf’ cell therapy products. They cover Artiva's "manufacturing first" approach to enabling scalable NK cell production, and much more.

  10. Inside A Dopamine-Restoring Cell Therapy For PD With BlueRock Therapeutics' Dr. Amit Rakhit 12/4/2024

    On this episode of Cell & Gene: The Podcast, Host Erin Harris, invites BlueRock Therapeutics' Dr. Amit Rakhit to take a deep dive into therapy options for Parkinson's disease (PD). They discuss how BlueRock's bemdaneprocel's mechanism of action differs from traditional PD treatments, the limitations of current PD medications, and much more.